Company Description
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States.
It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions.
The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.
It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V.; UCB Biopharma SRL; NE Scientific, LLC; and University of California, San Francisco, and Johns Hopkins University.
The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020.
ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
| Country | United States |
| Founded | 1998 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 115 |
| CEO | Joseph Burnett |
Contact Details
Address: 120 S. Sierra Avenue, Suite 100 Solana Beach, California 92075 United States | |
| Phone | 888 287 9109 |
| Website | clearpointneuro.com |
Stock Details
| Ticker Symbol | CLPT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1285550 |
| CUSIP Number | 18507C103 |
| ISIN Number | US18507C1036 |
| Employer ID | 58-2394628 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Joseph Michael Burnett | President, Chief Executive Officer and Director |
| Danilo D'Alessandro | Chief Financial Officer |
| Jeremy L. Stigall | Chief Business Officer |
| Mazin Sabra | Chief Operating Officer |
| Ellisa Cholapranee J.D. | General Counsel and Secretary |
| Dr. Paul S. Larson FAANS, M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 22, 2026 | EFFECT | Notice of Effectiveness |
| Jan 22, 2026 | 424B3 | Prospectus |
| Jan 14, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Jan 12, 2026 | 8-K | Current Report |
| Jan 9, 2026 | 144 | Filing |
| Jan 5, 2026 | 8-K | Current Report |
| Nov 20, 2025 | 8-K | Current Report |
| Nov 12, 2025 | 144 | Filing |
| Nov 12, 2025 | SCHEDULE 13G/A | Filing |
| Nov 6, 2025 | 10-Q | Quarterly Report |